News Quantified


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Ocugen to Present at April 2026 Investor and Industry Conferences

Ocugen (OCGN) Valuation Check After Encouraging Phase 2 ArMaDa Results For OCU410 [Yahoo! Finance]

OCU410's Phase 2 Gene-Agnostic Results in Dry AMD Might Change The Case For Investing In Ocugen (OCGN) [Yahoo! Finance]

Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress [Yahoo! Finance]

Ocugen (OCGN) was downgraded by Wall Street Zen from "hold" to "sell"

3/4/2026

08:15 am

ocgn

7.1%

IN-LINE

8/1/2025

08:25 am

ocgn

-4.5%

IN-LINE

5/9/2025

08:01 am

ocgn

-5.6%

BEAT

Oppenheimer Holdings, Inc.

Form PRER14A Ocugen, Inc.

Form PRE 14A Ocugen, Inc. For: Jun 11

Form SCHEDULE 13G Ocugen, Inc. Filed by: MILLENNIUM MANAGEMENT LLC

Form 4 Ocugen, Inc. For: Apr 01 Filed by: Zhang Junge

Form SCHEDULE 13G/A Ocugen, Inc. Filed by: VANGUARD GROUP INC

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}